This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Research article
Xiao Yu
Central South University Third Xiangya Hospital
Corresponding Author
ORCiD: https://orcid.org/0000-0002-3172-8606
License:
This work is licensed under a CC BY 4.0 License. Read Full License
The most recent version of this article is available here.
Background: Pancreatic cancer (PC) is characterized by high malignancy and poor prognosis. Detection of circulating microRNAs (miRNAs) is one of the liquid biopsy approaches. Numerous researches have suggested that some differentially expressed miRNAs may be promising diagnostic markers for PC, but the results varied among studies. The present study aimed to summarize the diagnostic accuracy of circulating miRNAs, carbohydrate antigen 19-9 (CA19-9), and the combination of miRNAs and CA19-9. Methods: A literature search of online databases including Pubmed, Embase, Cochrane Library, China National Knowledge Infrastructure (CNKI) and WanFang was conducted. Relative data were extracted from eligible included studies and a meta-analysis was performed. Results: A total of 46 studies involving 4,326 PC patients and 4,277 non-PC controls were included. The pooled sensitivity (SEN), specificity (SPE) and AUC of circulating miRNAs in differentiating PC from non-PC controls were 0.79 (0.77-0.81), 0.77 (0.75-0.79), and 0.85 (0.81-0.87), respectively. For CA19-9, the SEN, SPE and AUC were 0.78 (0.75-0.80), 0.90 (0.85-0.94) and 0.85 (0.82-0.88), respectively. The combination of miRNAs and CA19-9 greatly improved the SEN, SPE and AUC to 0.84 (0.80-0.87), 0.91 (0.89-0.93) and 0.94 (0.92-0.96), respectively. Circulating miRNAs also yielded an acceptable diagnostic accuracy for early-stage PC with SEN of 0.79 (0.76-0.82), SPE of 0.74 (0.68-0.79) and AUC of 0.81 (0.77-0.84). Conclusions: Circulating miRNAs exhibited a satisfactory diagnostic performance for PC, even early-stage PC. The combination of circulating miRNAs and the traditional marker CA19-9 can further improve the diagnostic accuracy, providing a novel strategy for PC diagnosis.
Keywords
pancreatic cancer; microRNAs; diagnosis; meta-analysis; circulating
Figure 1
Figure 2
This is a list of supplementary files associated with this preprint. Click to download.
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
No community comments so far
Version 2
Posted 02 Jan, 2020
No comments provided
No comments provided
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Learn more about our company.
This is a preprint. It has not completed peer review.
Research article
Xiao Yu
Central South University Third Xiangya Hospital
Corresponding Author
ORCiD: https://orcid.org/0000-0002-3172-8606
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
No community comments so far
Version 2
Posted 02 Jan, 2020
No comments provided
No comments provided
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
License:
This work is licensed under a CC BY 4.0 License. Read Full License
The most recent version of this article is available here.
Background: Pancreatic cancer (PC) is characterized by high malignancy and poor prognosis. Detection of circulating microRNAs (miRNAs) is one of the liquid biopsy approaches. Numerous researches have suggested that some differentially expressed miRNAs may be promising diagnostic markers for PC, but the results varied among studies. The present study aimed to summarize the diagnostic accuracy of circulating miRNAs, carbohydrate antigen 19-9 (CA19-9), and the combination of miRNAs and CA19-9. Methods: A literature search of online databases including Pubmed, Embase, Cochrane Library, China National Knowledge Infrastructure (CNKI) and WanFang was conducted. Relative data were extracted from eligible included studies and a meta-analysis was performed. Results: A total of 46 studies involving 4,326 PC patients and 4,277 non-PC controls were included. The pooled sensitivity (SEN), specificity (SPE) and AUC of circulating miRNAs in differentiating PC from non-PC controls were 0.79 (0.77-0.81), 0.77 (0.75-0.79), and 0.85 (0.81-0.87), respectively. For CA19-9, the SEN, SPE and AUC were 0.78 (0.75-0.80), 0.90 (0.85-0.94) and 0.85 (0.82-0.88), respectively. The combination of miRNAs and CA19-9 greatly improved the SEN, SPE and AUC to 0.84 (0.80-0.87), 0.91 (0.89-0.93) and 0.94 (0.92-0.96), respectively. Circulating miRNAs also yielded an acceptable diagnostic accuracy for early-stage PC with SEN of 0.79 (0.76-0.82), SPE of 0.74 (0.68-0.79) and AUC of 0.81 (0.77-0.84). Conclusions: Circulating miRNAs exhibited a satisfactory diagnostic performance for PC, even early-stage PC. The combination of circulating miRNAs and the traditional marker CA19-9 can further improve the diagnostic accuracy, providing a novel strategy for PC diagnosis.
Figure 1
Figure 2
Loading...